Mifsud Matthew J, Tanvetyanon Tawee, Mccaffrey Judith C, Otto Kristen J, Padhya Tapan A, Kish Julie, Trotti Andy M, Harrison Louis B, Caudell Jimmy J
Department of Otolaryngology - Head and Neck Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Department of Thoracic Oncology and Head and Neck and Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Head Neck. 2016 Nov;38(11):1628-1633. doi: 10.1002/hed.24484. Epub 2016 Apr 21.
Given the aggressive behavior of advanced salivary malignancies, the purpose of the current study was to explore the utility of adjuvant chemoradiotherapy (CRT) in this population.
A retrospective study of salivary carcinomas treated from 1998 to 2013 with postoperative CRT (37 patients) or radiotherapy (RT; 103 patients) was completed.
The decision to utilize adjuvant CRT versus RT was influenced by tumor grade and histology, cervical lymph node status, surgical margins, and perineural invasion. In both treatment cohorts, high locoregional control rates were obtained (79% for CRT vs 91% for RT; p = .031). Multivariate Cox regression analysis did not identify a difference in 3-year progression-free survival (PFS) with the use of CRT versus RT (hazard ratio [HR] = 0.783; 95% confidence interval [CI] = 0.396-1.549; p = .482).
Until prospective evidence is available, such as from Radiation Therapy Oncology Group 1008, the standard use of CRT for advanced salivary malignancies cannot be recommended. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.
鉴于晚期涎腺恶性肿瘤具有侵袭性，本研究旨在探讨辅助放化疗（CRT）在该人群中的应用价值。
完成了一项对1998年至2013年接受术后CRT（37例患者）或放疗（RT；103例患者）的涎腺癌患者的回顾性研究。
采用辅助CRT还是RT的决策受肿瘤分级和组织学、颈部淋巴结状态、手术切缘及神经周围侵犯的影响。在两个治疗队列中，均获得了较高的局部区域控制率（CRT组为79%，RT组为91%；p = 0.031）。多因素Cox回归分析未发现使用CRT与RT的3年无进展生存期（PFS）存在差异（风险比[HR] = 0.783；95%置信区间[CI] = 0.396 - 1.549；p = 0.482）。
在获得前瞻性证据（如来自放射肿瘤学组1008的证据）之前，不建议将CRT作为晚期涎腺恶性肿瘤的标准治疗方法。© 2016威利期刊公司。《头颈》38: 1708 - 1716，2016年。
Zotero 插件